MRC2 and prostate carcinoma: Given the expression of Endo180 observed in tumor cell foci in metastatic bone lesions [4], and increased levels of soluble Endo180 in the serum of patients with visceral and bone metastases [31], we hypothesized that Endo180 can regulate prostate cancer cell plasticity on the bone-like ECM derived from human osteoblasts and visceral tissue-like ECM derived from human fibroblasts.